An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.

•mEOC/GOG-0241 is one of the first international rare tumor trials.•Oxaliplatin/capecitabine might be worth further study. Long-term follow-up is feasible in rare tumors.•Challenges were lack of local resources and funding for experimental licenced therapies.